<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39701047</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9875</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>2</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Digestive diseases (Basel, Switzerland)</Title><ISOAbbreviation>Dig Dis</ISOAbbreviation></Journal><ArticleTitle>Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.</ArticleTitle><Pagination><StartPage>146</StartPage><EndPage>157</EndPage><MedlinePgn>146-157</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000543166</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Tenapanor is a first-in-class, minimally absorbed intestinal sodium/hydrogen exchanger isoform 3 inhibitor approved by the US Food and Drug Administration for adults with irritable bowel syndrome with constipation (IBS-C). Pooled data from the phase 2b (NCT01923428) and phase 3 T3MPO-1 (NCT02621892) and T3MPO-2 (NCT02686138) studies examined the effects of tenapanor on abdominal symptoms independent of tenapanor's effect on complete spontaneous bowel movement (CSBM) frequency in adults with IBS-C.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This post hoc analysis was performed for patients with no CSBMs in &#x2265;6 of the first 12 weeks of treatment (no-CSBM subgroup). The three-item abdominal score (AS3; the average of weekly abdominal pain, bloating, and discomfort scores) measured abdominal symptom response in tenapanor versus placebo. The overall change from baseline and response rate (improvement of &#x2265;2 points or a reduction of &#x2265;30%) in AS3 and individual abdominal scores during the 12 weeks were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the pooled safety analysis set (N = 1,382), 641 patients were classified as no-CSBM patients and 640 were included in the efficacy analysis. Among the no-CSBM subgroup, tenapanor-treated patients experienced a greater improvement in AS3 in week 12 versus placebo-treated patients (least squares mean change, -1.74 vs. -1.29; p = 0.007), and the AS3 responder rate was higher for tenapanor (40.2% vs. 29.6%; p = 0.008). Similar improvements were displayed across individual abdominal symptom scores. Diarrhea was the most common adverse event in tenapanor-treated patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C.</AbstractText><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Tenapanor is a first-in-class, minimally absorbed intestinal sodium/hydrogen exchanger isoform 3 inhibitor approved by the US Food and Drug Administration for adults with irritable bowel syndrome with constipation (IBS-C). Pooled data from the phase 2b (NCT01923428) and phase 3 T3MPO-1 (NCT02621892) and T3MPO-2 (NCT02686138) studies examined the effects of tenapanor on abdominal symptoms independent of tenapanor's effect on complete spontaneous bowel movement (CSBM) frequency in adults with IBS-C.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This post hoc analysis was performed for patients with no CSBMs in &#x2265;6 of the first 12 weeks of treatment (no-CSBM subgroup). The three-item abdominal score (AS3; the average of weekly abdominal pain, bloating, and discomfort scores) measured abdominal symptom response in tenapanor versus placebo. The overall change from baseline and response rate (improvement of &#x2265;2 points or a reduction of &#x2265;30%) in AS3 and individual abdominal scores during the 12 weeks were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the pooled safety analysis set (N = 1,382), 641 patients were classified as no-CSBM patients and 640 were included in the efficacy analysis. Among the no-CSBM subgroup, tenapanor-treated patients experienced a greater improvement in AS3 in week 12 versus placebo-treated patients (least squares mean change, -1.74 vs. -1.29; p = 0.007), and the AS3 responder rate was higher for tenapanor (40.2% vs. 29.6%; p = 0.008). Similar improvements were displayed across individual abdominal symptom scores. Diarrhea was the most common adverse event in tenapanor-treated patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Darren M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayuk</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>Brooks D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Health Science Center, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Lucinda A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Alix School of Medicine, Division of Gastroenterology and Hepatology, Scottsdale, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahuja</LastName><ForeName>Nitin K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Jill K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Section of Digestive Diseases, Department of Internal Medicine, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Suling</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenbaum</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Ardelyx, Inc., Waltham, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lembo</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dig Dis</MedlineTA><NlmUniqueID>8701186</NlmUniqueID><ISSNLinking>0257-2753</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>WYD79216A6</RegistryNumber><NameOfSubstance UI="C000599417">tenapanor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003248" MajorTopicYN="Y">Constipation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="Y">Defecation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="Y">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007546" MajorTopicYN="N" AutoHM="Y">Isoquinolines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal score</Keyword><Keyword MajorTopicYN="N">Abdominal symptoms</Keyword><Keyword MajorTopicYN="N">Constipation</Keyword><Keyword MajorTopicYN="N">Irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">Tenapanor</Keyword></KeywordList><CoiStatement>Darren M. Brenner is a consultant, advisor, and/or speaker for Anji, Ardelyx, AbbVie, Alnylam, Salix, Ironwood, Takeda, Bayer, Gemelli, Redhill, Mahana, Laborie, Owlstone, Entrinsic Bioscience, Vibrant, CinPhloro. Dr. Reddy is a member of the Board of Directors of the International Foundation for GI Disorders (IFFGD). Gregory S. Sayuk is a consultant and speaker for Salix Pharmaceuticals, AbbVie/Ironwood Pharmaceuticals, Sanofi/Regeneron, Phathom, and Ardelyx, Inc., and is a consultant for the GI Health Foundation and Rome Foundation. Brooks D. Cash is a consultant and speaker for AbbVie, Inc, Alnylam Pharmaceuticals, Inc, Ardelyx, QOL Medical, Phathom Pharmaceuticals, Takeda Pharmaceuticals, and Salix Pharmaceuticals and has received research support from Napo Pharmaceuticals, Inc. Lucinda A. Harris has received financial support for consulting from Ardelyx, Inc., AbbVie, Alnylam, Ironwood, Gemelli Biotech, and Salix, and research support from Takeda. Nitin K. Ahuja has served as a consultant for Ardelyx and Haleon and received research support from Vanda Pharmaceuticals. Jill K. Deutsch has no relevant disclosures. Yang Yang, Suling Zhao, and David P. Rosenbaum are employees of Ardelyx, Inc. Anthony J. Lembo is a consultant for Allergan, Ardelyx, Atmo, Allakos, BioAmerica, AEON, Arena, Takeda, Evoke Pharma, Ironwood Pharmaceuticals, Gemelli, Alkermes, Pfizer, OrthoMed, and Vibrant and has stock with Johnson &amp; Johnson, Bristol Myers Squibb, and Allurion.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>19</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39701047</ArticleId><ArticleId IdType="pmc">PMC11965839</ArticleId><ArticleId IdType="doi">10.1159/000543166</ArticleId><ArticleId IdType="pii">000543166</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almario CV, Sharabi E, Chey WD, Lauzon M, Higgins CS, Spiegel BMR. Prevalence and burden of illness of Rome IV irritable bowel syndrome in the United States: results from a nationwide cross-sectional study. Gastroenterology. 2023;165(6):1475&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">37595647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. . ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. . Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99&#x2013;114.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Almario CV, Spiegel BM, Chey WD. Presentation and characteristics of abdominal pain vary by irritable bowel syndrome subtype: results of a nationwide population-based study. Am J Gastroenterol. 2020;115(2):294&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7469977</ArticleId><ArticleId IdType="pubmed">31913193</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ, et al. . Development of the Diary for Irritable Bowel Syndrome Symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health. 2017;20(4):618&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">28408004</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):580&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4424385</ArticleId><ArticleId IdType="pubmed">25781368</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22(4):558&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056566</ArticleId><ArticleId IdType="pubmed">27431236</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy L, Erickson A, Brierley SM. Visceral pain. Annu Rev Physiol. 2019;81:261&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">30379615</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. . Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. 2016;65(1):155&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">26194403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanning N, Edwinson AL, Ceuleers H, Peters SA, De Man JG, Hassett LC, et al. . Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7925957</ArticleId><ArticleId IdType="pubmed">33717210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bischoff SC, Giovanni B, Buurman W, Ockhuizen T, Schulzke J, Serino M, et al. . Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14(189):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4253991</ArticleId><ArticleId IdType="pubmed">25407511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Cangemi D, Vazquez-Roque M. Management of chronic abdominal distension and bloating. Clin Gastroenterol Hepatol. 2021;19(2):219&#x2013;31.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">32246999</ArticleId></ArticleIdList></Reference><Reference><Citation>Tack J, Stanghellini V, Mearin F, Yiannakou Y, Layer P, Coffin B, et al. . Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19(1):69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6505116</ArticleId><ArticleId IdType="pubmed">31064345</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DCA, Abel JL, Martin C, Doshi JA, Essoi B, Korrer S, et al. . Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR). J Med Econ. 2020;23(10):1072&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">32696684</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Caballero AM, Serra J, Brotons C, Tantina A, Fort E, et al. . A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain. Gastroenterol Hepatol. 2019;42(3):141&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30612850</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangan V, Ballou S, Shin A, Camilleri M; Beth Israel Deaconess Medical Center GI Motility Working Group; Lembo A. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America Survey. Gastroenterology. 2020;158(3):786&#x2013;8.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7212496</ArticleId><ArticleId IdType="pubmed">31711922</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon CD, Hanlon J, Abel JL, Lundy JJ, Carson RT, Reasner DS. Psychometric analysis of the abdominal score from the diary for irritable bowel syndrome symptoms-constipation using phase IIb clinical trial data. Value Health. 2020;23(3):362&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32197732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Lacy BE, Moshiree B, Kassebaum A, Abel JL, Hanlon J, et al. . Efficacy of linaclotide in reducing abdominal symptoms of bloating, discomfort, and pain: a phase 3b trial using a novel abdominal scoring system. Am J Gastroenterol. 2021;116(9):1929&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">34465695</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ardelyx, Inc . IBSRELA Prescribing Information. Waltman MA:  [cited 2023 Oct 1]. Available from: https://ardelyx.com/wp-content/uploads/2021/11/IBSRELA-Prescribing-Information-1.pdf</Citation></Reference><Reference><Citation>Jacobs JW, Leadbetter MR, Bell N, Koo-McCoy S, Carreras CW, He L, et al. . Discovery of tenapanor: a first-in-class minimally systemic inhibitor of intestinal Na+/H+ exchanger isoform 3. ACS Med Chem Lett. 2022;13(7):1043&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9290029</ArticleId><ArticleId IdType="pubmed">35859876</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig. 2018;38(4):341&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856883</ArticleId><ArticleId IdType="pubmed">29363027</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5486465</ArticleId><ArticleId IdType="pubmed">27368672</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, et al. . Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">24622516</ArticleId></ArticleIdList></Reference><Reference><Citation>King AJ, Chang L, Li Q, Liu L, Zhu Y, Pasricha PJ, et al. . NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons. Am J Physiol Gastrointest Liver Physiol. 2024;326(5):G543&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11376972</ArticleId><ArticleId IdType="pubmed">38252683</ArticleId></ArticleIdList></Reference><Reference><Citation>King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, et al. . Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10(456):eaam6474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454550</ArticleId><ArticleId IdType="pubmed">30158152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017;112(5):763&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5418559</ArticleId><ArticleId IdType="pubmed">28244495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7771640</ArticleId><ArticleId IdType="pubmed">31934897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021;116(6):1294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183489</ArticleId><ArticleId IdType="pubmed">33337659</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383110</ArticleId><ArticleId IdType="pubmed">28274109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo AJ, Friedenberg KA, Fogel RP, Edelstein S, Zhao S, Yang Y, et al. . Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study. Neurogastroenterol Motil. 2023;35(11):e14658.</Citation><ArticleIdList><ArticleId IdType="pubmed">37668173</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Sayuk GS, Rosenbaum DP, Edelstein S, Kozuka K, Chang L. An overview of the effects of tenapanor on visceral hypersensitivity in the treatment of irritable bowel syndrome with constipation. Clin Exp Gastroenterol. 2024;17:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11016248</ArticleId><ArticleId IdType="pubmed">38617992</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, et al. . Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19006537</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. . Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22986437</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner DM, Fogel R, Dorn SD, Krause R, Eng P, Kirshoff R, et al. . Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018;113(5):735&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">29545635</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>